Inge M W Verberk
Overview
Explore the profile of Inge M W Verberk including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
56
Citations
1933
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Oomens J, Moonen J, Vos S, Beran M, Mateus P, De Deyn P, et al.
BMC Neurol
. 2025 Feb;
25(1):59.
PMID: 39939930
Background: Aggregation of cohort data increases precision for studying neurodegenerative disease pathways, but efforts to combine data and expertise are often hampered by infrastructural, ethical and legal considerations. We aimed...
2.
Wojdala A, Vanbrabant J, Bayoumy S, Antwi-Berko D, Le Bastard N, van der Flier W, et al.
Alzheimers Res Ther
. 2024 Dec;
16(1):266.
PMID: 39702308
Background: Among the Alzheimer's disease (AD) biomarkers measured in blood, phosphorylated forms of tau (p-tau) have been shown to exhibit a particularly high diagnostic potential. Here, we performed a comprehensive...
3.
Rousset R, den Braber A, Verberk I, Boonkamp L, Wilson D, Ligthart L, et al.
Alzheimers Dement
. 2024 Nov;
21(1):e14269.
PMID: 39588748
Introduction: Alzheimer's disease (AD) is a highly heritable disease (60%-80%). Amyloid beta (Aβ) 42/40, neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP) are plasma biomarkers for AD. Clinical...
4.
Rousset R, Claessen T, Van Harten A, Lemstra A, Pijnenburg Y, van der Flier W, et al.
Alzheimers Dement (Amst)
. 2024 Nov;
16(4):e70003.
PMID: 39583647
Introduction: Plasma phosphorylated tau-217 (p-tau217) and neurofilament light (NfL) can differentiate between different dementias in selected cohorts. We aim to test the discrimination potential of these markers in a real-world...
5.
Del Campo M, Quesada C, Vermunt L, Peeters C, Hok-A-Hin Y, Trieu C, et al.
Mol Neurodegener
. 2024 Nov;
19(1):82.
PMID: 39523360
This preclinical AD CSF proteome study identified a panel of 12-CSF markers detecting amyloid positivity and clinical progression to AD with high accuracy; some of these CSF proteins related to...
6.
Le Scouarnec L, Bouteloup V, van der Veere P, van der Flier W, Teunissen C, Verberk I, et al.
Alzheimers Res Ther
. 2024 Oct;
16(1):219.
PMID: 39394180
Background: The accumulation of amyloid-β (Aβ) peptide in the brain is a hallmark of Alzheimer's disease (AD), occurring years before symptom onset. Current methods for quantifying in vivo amyloid load...
7.
Scholl M, Verberk I, Del Campo M, Delaby C, Therriault J, Chong J, et al.
Lancet Healthy Longev
. 2024 Oct;
5(10):100630.
PMID: 39369727
Blood biomarkers have emerged as accessible, cost-effective, and highly promising tools for advancing the diagnostics of Alzheimer's disease. However, transitioning from cerebrospinal fluid biomarkers to blood biomarkers-eg, to verify amyloid...
8.
Gogishvili D, Honey M, Verberk I, Vermunt L, Hol E, Teunissen C, et al.
J Neurochem
. 2024 Sep;
169(1):e16226.
PMID: 39289040
Glial fibrillary acidic protein (GFAP) is a well-established biomarker of reactive astrogliosis in the central nervous system because of its elevated levels following brain injury and various neurological disorders. The...
9.
Bader I, Groot C, Tan H, Milongo J, den Haan J, Verberk I, et al.
Alzheimers Res Ther
. 2024 Aug;
16(1):190.
PMID: 39169442
Background: Alzheimer's disease (AD) is a common, complex and multifactorial disease that may require screening across multiple routes of referral to enable early detection and subsequent future implementation of tailored...
10.
Verberk I, Jutte J, Kingma M, Vigneswaran S, Gouda M, van Engelen M, et al.
Alzheimers Dement
. 2024 Aug;
20(9):6115-6132.
PMID: 39096164
Introduction: We developed a multimarker blood test result interpretation tool for the clinical dementia practice, including phosphorylated (P-)tau181, amyloid-beta (Abeta)42/40, glial fibrillary acidic protein (GFAP), and neurofilament light (NfL). Methods:...